anlotinib + oxaliplatin + capecitabine

Anlotinib + oxaliplatin + capecitabine is a three-drug combination regimen used primarily as first-line therapy for unresectable or metastatic colorectal cancer, particularly in patients with RAS/BRAF wild-type tumors. Anlotinib is an oral small molecule multi-target tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors 1–3 (VEGFR1–3), fibroblast growth factor receptors 1–4 (FGFR1–4), platelet-derived growth factor receptors alpha/beta (PDGFRα/β), and c-kit, thereby inhibiting tumor angiogenesis and proliferation. Oxaliplatin is a platinum-based chemotherapeutic agent that induces DNA crosslinking, leading to apoptosis in rapidly dividing cells. Capecitabine is an oral prodrug converted to 5-fluorouracil, which inhibits thymidylate synthase and disrupts DNA synthesis in cancer cells. This regimen has demonstrated promising objective response rates, disease control rates, progression-free survival, overall survival, and manageable toxicity profiles in clinical trials for metastatic colorectal cancer[1][2][3][4][6].

Brand names

XELOX

Other names

XELOX (for the combination of capecitabine and oxaliplatin)CAPEOX (alternative name for the combination of capecitabine and oxaliplatin)